Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) – Investment analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for shares of Neurocrine Biosciences in a research report issued on Thursday, February 8th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of $5.05 for the year, up […]
Fiera Capital Corp boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 42.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 511,368 shares of the company’s stock after acquiring an additional 153,393 shares during the quarter. Fiera Capital Corp owned about […]
Andra AP fonden reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 19.6% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 54,600 shares of the company’s stock after selling 13,300 shares during the period. Andra AP fonden’s holdings in Neurocrine Biosciences were worth $6,142,000 as of its most recent filing […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider David W. Boyer sold 1,328 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $135.41, for a total transaction of $179,824.48. Following the sale, the insider now directly owns 4,895 shares of the company’s […]